A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Severe Preeclampsia.

Trial Profile

A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Severe Preeclampsia.

Suspended
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Preeclampsia
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 05 Dec 2006 Status change
    • 29 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top